On May 21, 2025, Sensei Biotherapeutics, Inc. held its annual stockholder meeting, in which directors were elected, Deloitte & Touche LLP was approved as the accounting firm for 2025, and a reverse stock split was sanctioned with a 1-for-10 to 1-for-30 ratio. A total of 65.92% of shares were represented at the meeting, leading to the approval of all proposals.